Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Sinai Health System has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 3 distinct examiners and 3 distinct art units. This direct ratio across examiners and units suggests a diverse range of biotechnology applications that are each being reviewed in a unique environment. The use of 3 distinct art units indicates that the health system's research is broad enough to trigger reviews from three different specialized divisions within the patent office.
The busiest examiner, KRISHNAN, GANAPATHY, is responsible for 1 busiest examiner pending office action. This is a portion of the 3 pending office actions. Because the 3 pending office actions are spread across 3 distinct examiners, the health system must manage independent prosecution timelines. Practitioners should be prepared for varying interpretations of pharmaceutical claims, as each 1 busiest examiner pending office action is subject to the specific standards of a different art unit. This distribution across 3 distinct art units highlights the breadth of the system's current intellectual property efforts in the biotechnology field.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KRISHNAN, GANAPATHY | 1 | 52.7% | +1.3% |
| LU, FRANK WEI MIN | 1 | 62.7% | +67.9% |
| WILSON, MICHAEL C | 1 | 41.5% | +17.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18284614 | COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS | KRISHNAN, GANAPATHY | 15d overdue |
| 17825784 | TOOLS AND METHODS FOR USING CELL DIVISION LOCI TO CONTROL PROLIFERATION OF CELLS | WILSON, MICHAEL C | 79d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17825784 | TOOLS AND METHODS FOR USING CELL DIVISION LOCI TO CONTROL PROLIFERATION OF CELLS | WILSON, MICHAEL C | 79d |
| 18059370 | METHODS OF CAPTURING CELL-FREE METHYLATED DNA AND USES OF SAME | LU, FRANK WEI MIN | — |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| 1683 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18284614 | COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS | KRISHNAN, GANAPATHY | 1693 | §102§103 | Final Rejection | 15d overdue | Pending | Sep 28, 2023 |
| 18059370 | METHODS OF CAPTURING CELL-FREE METHYLATED DNA AND USES OF SAME | LU, FRANK WEI MIN | 1683 | §102§103§112DP | Non-Final OA | — | Pending | Nov 28, 2022 |
| 17825784 | TOOLS AND METHODS FOR USING CELL DIVISION LOCI TO CONTROL PROLIFERATION OF CELLS | WILSON, MICHAEL C | 1638 | §103§112Other | Non-Final OA | 79d | Pending | May 26, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSinai Health System has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Ganapathy Krishnan has the most, with 1 of Sinai Health System's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
